VERTEX PHARMACEUTICALS INC / MA— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$25.64B
↑+13.8% +$3.11Bvs FY2024
Total Liabilities
$6.98B
↑+13.9% +$854Mvs FY2024
Equity
$18.67B
↑+13.7% +$2.26Bvs FY2024
Cash
$5.08B
↑+11.3% +$515Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $25.64B | $22.53B |
| Current Assets | $11.20B | $9.60B |
| Cash | $5.08B | $4.57B |
| ST Investments | $1.52B | $1.55B |
| Receivables | $2.05B | $1.61B |
| Inventory | $1.69B | $1.21B |
| Other Current | $853M | $666M |
| Non-Current Assets | $14.44B | $12.94B |
| PPE | $0 | $0 |
| Goodwill | $1.09B | $1.09B |
| Intangibles | $424M | $826M |
| Investments | $5.71B | $5.11B |
| Other Non-Current | $7.22B | $5.92B |
| Total Liab+Eq | $25.64B | $22.53B |
| Current Liab. | $3.86B | $3.56B |
| Accounts Payable | $462M | $413M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $3.40B | $3.15B |
| Non-Current Liab. | $3.12B | $2.56B |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $3.12B | $2.56B |
| Equity | $18.67B | $16.41B |
| Retained Earnings | $13.56B | $9.61B |
| Other Equity | $5.11B | $6.80B |
QuarterCharts · SEC EDGAR data · VRTX · Comparing FY2025 vs FY2024